Gastric and Gastroesophageal Junction Adenocarcinoma Market Growth, Trends, Analysis and Forecast
- Submitted by: Marketreport
- Views: 87
- Category: Other
- Date Submitted: 07/18/2016 01:34 AM
- Pages: 3
- Report this Essay
Summary
Gastric and gastroesophageal junction adenocarcinoma (G/GEJAC) represents the majority of gastric cancer cases worldwide. It is the fifth most diagnosed cancer globally, and the third most common cause of cancer death in the world. The major treatments for G/GEJAC are chemotherapy-based, but targeted therapies such as HER2 and angiogenesis inhibitors have been approved and are being added to chemotherapy regimens since 2010 and 2014, respectively.
The US is a large G/GEJAC market due to high treatment rates of advanced diseases and higher drug prices than in the rest of the 8MM. Increased sales of G/GEJAC therapies over the forecast period will be driven by increasing disease incident cases, the rapid uptake of newly approved Cyramza, and the approval and increasing uptake of expensive pipeline agents, such as anti-PD-1 immunotherapies and a HER2-targeted therapy.
*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.
Browse full report with TOC@ https://marketreportscenter.com/reports/327247/gastric-and-gastroesophageal-junction-adenocarcinoma-us-drug-forecast-and-market-analysis-to-2024
Scope
- Overview of G/GEJAC including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2014-2024.
- Analysis of the impact of key events as well the drivers and restraints affecting the US G/GEJAC market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for G/GEJAC.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
-...
Gastric and gastroesophageal junction adenocarcinoma (G/GEJAC) represents the majority of gastric cancer cases worldwide. It is the fifth most diagnosed cancer globally, and the third most common cause of cancer death in the world. The major treatments for G/GEJAC are chemotherapy-based, but targeted therapies such as HER2 and angiogenesis inhibitors have been approved and are being added to chemotherapy regimens since 2010 and 2014, respectively.
The US is a large G/GEJAC market due to high treatment rates of advanced diseases and higher drug prices than in the rest of the 8MM. Increased sales of G/GEJAC therapies over the forecast period will be driven by increasing disease incident cases, the rapid uptake of newly approved Cyramza, and the approval and increasing uptake of expensive pipeline agents, such as anti-PD-1 immunotherapies and a HER2-targeted therapy.
*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.
Browse full report with TOC@ https://marketreportscenter.com/reports/327247/gastric-and-gastroesophageal-junction-adenocarcinoma-us-drug-forecast-and-market-analysis-to-2024
Scope
- Overview of G/GEJAC including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2014-2024.
- Analysis of the impact of key events as well the drivers and restraints affecting the US G/GEJAC market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for G/GEJAC.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
-...